NASDAQ:TCON
TRACON Pharmaceuticals Stock News
$1.43
-0.100 (-6.54%)
At Close: May 17, 2024
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
08:05am, Thursday, 02'nd Jun 2022
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
08:05am, Monday, 16'th May 2022
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q1 2022 Results - Earnings Call Transcript
11:36pm, Wednesday, 11'th May 2022
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Charles Theuer – President and Chief Executive Officer Scott Brown – Chief
TRACON Pharmaceuticals says it is on track to release new efficacy data from ENVASARC protocol later this year
05:01pm, Wednesday, 11'th May 2022
TRACON Pharmaceuticals (NASDAQ:TCON) Inc CEO Charles Theuer said the biopharmaceutical company remains on track to release interim efficacy data from its recently approved amended ENVASARC protocol,
Follow the Insiders and Buy the Dip in These 3 Stocks
03:15pm, Friday, 06'th May 2022
These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.
TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022
08:05am, Wednesday, 04'th May 2022
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON Pharmaceuticals receives amended ENVASARC protocol approval for its US and UK clinical sites
11:21am, Tuesday, 19'th Apr 2022
TRACON Pharmaceuticals (NASDAQ:TCON) Inc announced that the amended ENVASARC protocol approved by the US Food and Drug Administration (FDA) in February has now been approved by institutional review bo
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
05:02pm, Friday, 08'th Apr 2022
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech S
TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference
08:05am, Wednesday, 23'rd Mar 2022
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q4 2021 Results - Earnings Call Transcript
02:00am, Wednesday, 16'th Mar 2022 Seeking AlphaTRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q4 2021 Results - Earnings Call Transcript
10:00pm, Tuesday, 15'th Mar 2022
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q4 2021 Results - Earnings Call Transcript
Tracon GAAP EPS of -$0.40 misses by $0.04
08:25pm, Tuesday, 15'th Mar 2022 Seeking Alpha
Tracon press release (TCON): Q4 GAAP EPS of -$0.40 misses by $0.04.Cash, cash equivalents and short-term investments were $24.1 million at December 31, 2021, compared to $36.1 million…
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
08:02pm, Tuesday, 15'th Mar 2022 GlobeNewswire
Announced FDA Approval of Amended ENVASARC Protocol, ENVASARC Interim Efficacy Data on Track for 2H22 Initiating combination trial of proprietary CTLA-4 with envafolimab in 2022
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides ...
08:02pm, Tuesday, 15'th Mar 2022 The Bakersfield Californian
Announced FDA Approval of Amended ENVASARC Protocol, ENVASARC Interim Efficacy Data on Track for 2H22 Initiating combination trial of proprietary CTLA-4 with envafolimab in 2022
TRACON Pharmaceuticals ends FY2021 with $24.1M in the bank; reveals key milestones for 2022
04:50pm, Tuesday, 15'th Mar 2022
TRACON Pharmaceuticals (NASDAQ:TCON) Inc said it has ended its fiscal year 2021 with cash and equivalents of $24.1 million as of December 31, 2021, as the company outlined some key milestones for the
